Adlai Nortye Ltd.

Contributing Author

Recent Articles by Adlai Nortye Ltd.

Feb-12	Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations ANL GlobeNewswire
Feb-03	Adlai Nortye Announces $140.0 Million Private Placement Equity Financing ANL GlobeNewswire
Dec-29	Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China ANL +9.76% GlobeNewswire
Nov-21	Adlai Nortye to Participate in Upcoming Investor Conferences ANL -5.59% GlobeNewswire
Oct-22	Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ANL GlobeNewswire
Oct-13	Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ANL +5.15% GlobeNewswire